The Experts below are selected from a list of 228 Experts worldwide ranked by ideXlab platform

Allan D. Sniderman - One of the best experts on this subject based on the ideXlab platform.

  • Reliability of low-density Lipoprotein Cholesterol, non-high-density Lipoprotein Cholesterol, and apoLipoprotein B measurement.
    Journal of clinical lipidology, 2011
    Co-Authors: John H. Contois, G. Russell Warnick, Allan D. Sniderman
    Abstract:

    There is little understanding of the reliability of laboratory measurements among clinicians. Low-density Lipoprotein Cholesterol (LDL-C) measurement is the cornerstone of cardiovascular risk assessment and prevention, but it is fraught with error. Therefore, we have reviewed issues related to accuracy and precision for the measurement of LDL-C and the related markers non-high-density Lipoprotein Cholesterol (non-HDL-C) and apoLipoprotein B. Despite the widespread belief that LDL-C is standardized and reproducible, available data suggest that results can vary significantly as the result of methods from different manufacturers. Similar problems with direct HDL-C assays raise concerns about the reliability of non-HDL-C measurement. The root cause of method-specific bias relates to the ambiguity in the definition of both LDL and HDL, and the heterogeneity of LDL and HDL particle size and composition. ApoLipoprotein B appears to provide a more reliable alternative, but assays for it have not been as rigorously tested as direct LDL-C and HDL-C assays.

  • a meta analysis of low density Lipoprotein Cholesterol non high density Lipoprotein Cholesterol and apoLipoprotein b as markers of cardiovascular risk
    Circulation-cardiovascular Quality and Outcomes, 2011
    Co-Authors: Allan D. Sniderman, John H. Contois, Matthew J. Mcqueen, Kenneth M Williams, Howard M Monroe, Jacqueline De Graaf, Curt D. Furberg
    Abstract:

    Background—Whether apoLipoprotein B (apoB) or non-high-density Lipoprotein Cholesterol (HDL-C) adds to the predictive power of low-density Lipoprotein Cholesterol (LDL-C) for cardiovascular risk remains controversial. Methods and Results—This meta-analysis is based on all the published epidemiological studies that contained estimates of the relative risks of non-HDL-C and apoB of fatal or nonfatal ischemic cardiovascular events. Twelve independent reports, including 233 455 subjects and 22 950 events, were analyzed. All published risk estimates were converted to standardized relative risk ratios (RRRs) and analyzed by quantitative meta-analysis using a random-effects model. Whether analyzed individually or in head-to-head comparisons, apoB was the most potent marker of cardiovascular risk (RRR, 1.43; 95% CI, 1.35 to 1.51), LDL-C was the least (RRR, 1.25; 95% CI, 1.18 to 1.33), and non-HDL-C was intermediate (RRR, 1.34; 95% CI, 1.24 to 1.44). The overall comparisons of the within-study differences showed t...

  • Why is non−high-density Lipoprotein Cholesterol a better marker of the risk of vascular disease than low-density Lipoprotein Cholesterol?
    Journal of clinical lipidology, 2010
    Co-Authors: Allan D. Sniderman, John H. Contois, Matthew J. Mcqueen, Kenneth R. Williams, Curt D. Furberg
    Abstract:

    Abstract Low-density Lipoprotein Cholesterol (LDL-C) has been the focus of managing Lipoprotein disorders for decades. It is now time to consider a change. Both apoLipoprotein B (apoB) and non-high-density Lipoprotein Cholesterol (HDL-C) have been shown to be more accurate markers of cardiovascular risk than LDL-C. ApoB measures total atherogenic particle number, of which 90% are LDL particles. Therefore, LDL particle number determines plasma apoB in most patients. Non-HDL-C is widely assumed to be superior to LDL-C when triglyceride concentrations are elevated (even modestly) because it includes the Cholesterol in very-low-density Lipoprotein. However, evidence does not support this concept. Rather, non-HDL-C appears to be an indirect way of estimating apoB. We argue that we should integrate the information from non-HDL-C and apoB for better risk assessment and a better target of therapy.

  • Assessment of reaching goal in patients with combined hyperlipidemia: low-density Lipoprotein Cholesterol, non-high-density Lipoprotein Cholesterol, or apoLipoprotein B.
    The American journal of cardiology, 2005
    Co-Authors: Evan A. Stein, Allan D. Sniderman, Peter M. Laskarzewski
    Abstract:

    It is well established that patients with combined hyperlipidemia, defined as elevated triglyceride levels between 200 and 500 mg/dL and elevated low-density Lipoprotein Cholesterol >130 mg/dL, are at increased risk for coronary artery disease. The optimal assessment of reaching lipid goals in patients with combined hyperlipidemia is still far from settled and has been an area of revision and modification in recent guidelines. Although controversy remains as to the best single measurement to be used in treatment goals, current focus is on the use of low-density Lipoprotein Cholesterol, non-high-density Lipoprotein Cholesterol, and apoLipoprotein B. This article reviews the use of these 3 biomarkers in assessing cardiovascular risk, and the strategies for managing combined hyperlipidemia.

  • Assessment of Reaching Goal in Patients with Combined Hyperlipidemia: Low-Density Lipoprotein Cholesterol, Non–High-Density Lipoprotein Cholesterol, or ApoLipoprotein B
    The American Journal of Cardiology, 2005
    Co-Authors: Evan A. Stein, Allan D. Sniderman, Peter M. Laskarzewski
    Abstract:

    It is well established that patients with combined hyperlipidemia, defined as elevated triglyceride levels between 200 and 500 mg/dL and elevated low-density Lipoprotein Cholesterol >130 mg/dL, are at increased risk for coronary artery disease. The optimal assessment of reaching lipid goals in patients with combined hyperlipidemia is still far from settled and has been an area of revision and modification in recent guidelines. Although controversy remains as to the best single measurement to be used in treatment goals, current focus is on the use of low-density Lipoprotein Cholesterol, non–high-density Lipoprotein Cholesterol, and apoLipoprotein B. This article reviews the use of these 3 biomarkers in assessing cardiovascular risk, and the strategies for managing combined hyperlipidemia.

Peter M. Laskarzewski - One of the best experts on this subject based on the ideXlab platform.

  • Assessment of reaching goal in patients with combined hyperlipidemia: low-density Lipoprotein Cholesterol, non-high-density Lipoprotein Cholesterol, or apoLipoprotein B.
    The American journal of cardiology, 2005
    Co-Authors: Evan A. Stein, Allan D. Sniderman, Peter M. Laskarzewski
    Abstract:

    It is well established that patients with combined hyperlipidemia, defined as elevated triglyceride levels between 200 and 500 mg/dL and elevated low-density Lipoprotein Cholesterol >130 mg/dL, are at increased risk for coronary artery disease. The optimal assessment of reaching lipid goals in patients with combined hyperlipidemia is still far from settled and has been an area of revision and modification in recent guidelines. Although controversy remains as to the best single measurement to be used in treatment goals, current focus is on the use of low-density Lipoprotein Cholesterol, non-high-density Lipoprotein Cholesterol, and apoLipoprotein B. This article reviews the use of these 3 biomarkers in assessing cardiovascular risk, and the strategies for managing combined hyperlipidemia.

  • Assessment of Reaching Goal in Patients with Combined Hyperlipidemia: Low-Density Lipoprotein Cholesterol, Non–High-Density Lipoprotein Cholesterol, or ApoLipoprotein B
    The American Journal of Cardiology, 2005
    Co-Authors: Evan A. Stein, Allan D. Sniderman, Peter M. Laskarzewski
    Abstract:

    It is well established that patients with combined hyperlipidemia, defined as elevated triglyceride levels between 200 and 500 mg/dL and elevated low-density Lipoprotein Cholesterol >130 mg/dL, are at increased risk for coronary artery disease. The optimal assessment of reaching lipid goals in patients with combined hyperlipidemia is still far from settled and has been an area of revision and modification in recent guidelines. Although controversy remains as to the best single measurement to be used in treatment goals, current focus is on the use of low-density Lipoprotein Cholesterol, non–high-density Lipoprotein Cholesterol, and apoLipoprotein B. This article reviews the use of these 3 biomarkers in assessing cardiovascular risk, and the strategies for managing combined hyperlipidemia.

Mikel Aickin - One of the best experts on this subject based on the ideXlab platform.

  • Resistance Exercise Training Is Associated With Decreases in Serum Low-Density Lipoprotein Cholesterol Levels in Premenopausal Women
    Archives of internal medicine, 1993
    Co-Authors: Thomas W. Boyden, Richard W. Pamenter, Scott B. Going, Timothy G. Lohman, M. C. Hall, Linda Houtkooper, Joy C. Bunt, Cheryl Ritenbaugh, Mikel Aickin
    Abstract:

    Background: Aerobic exercise training is associated with reduced serum concentrations of triglycerides, increased concentrations of high-density Lipoprotein Cholesterol, and minimal changes in serum levels of total Cholesterol or low-density Lipoprotein Cholesterol. There are few data on the effects of resistance exercise on blood lipid levels. Methods: Premenopausal women were randomly assigned to a supervised resistance exercise training program (n=46) or a control group (n=42) for 5 months. Serum was analyzed for levels of total Cholesterol, low-density Lipoprotein Cholesterol, high-density Lipoprotein Cholesterol, and triglycerides. Body composition and dietary intake were also measured. Results: The exercise group showed a 0.33±0.03-mmol/L (mean ± SE) decrease in total Cholesterol level and a 0.36±0.001-mmol/L decrease in low-density Lipoprotein Cholesterol level that was significantly different from the control group. No significant changes were noted in serum high-density Lipoprotein Cholesterol or triglyceride levels in either group. Changes in body composition showed no significant correlations with changes in total Cholesterol or low-density Lipoprotein Cholesterol. There were no significant differences in nutrient intake between the groups. Conclusion: In healthy, premenopausal women, with normal baseline lipid profiles, 5 months of resistance exercise training was associated with significant decreases in serum total Cholesterol and low-density Lipoprotein Cholesterol concentrations. (Arch Intern Med. 1993;153:97-100)

Evan A. Stein - One of the best experts on this subject based on the ideXlab platform.

  • Assessment of reaching goal in patients with combined hyperlipidemia: low-density Lipoprotein Cholesterol, non-high-density Lipoprotein Cholesterol, or apoLipoprotein B.
    The American journal of cardiology, 2005
    Co-Authors: Evan A. Stein, Allan D. Sniderman, Peter M. Laskarzewski
    Abstract:

    It is well established that patients with combined hyperlipidemia, defined as elevated triglyceride levels between 200 and 500 mg/dL and elevated low-density Lipoprotein Cholesterol >130 mg/dL, are at increased risk for coronary artery disease. The optimal assessment of reaching lipid goals in patients with combined hyperlipidemia is still far from settled and has been an area of revision and modification in recent guidelines. Although controversy remains as to the best single measurement to be used in treatment goals, current focus is on the use of low-density Lipoprotein Cholesterol, non-high-density Lipoprotein Cholesterol, and apoLipoprotein B. This article reviews the use of these 3 biomarkers in assessing cardiovascular risk, and the strategies for managing combined hyperlipidemia.

  • Assessment of Reaching Goal in Patients with Combined Hyperlipidemia: Low-Density Lipoprotein Cholesterol, Non–High-Density Lipoprotein Cholesterol, or ApoLipoprotein B
    The American Journal of Cardiology, 2005
    Co-Authors: Evan A. Stein, Allan D. Sniderman, Peter M. Laskarzewski
    Abstract:

    It is well established that patients with combined hyperlipidemia, defined as elevated triglyceride levels between 200 and 500 mg/dL and elevated low-density Lipoprotein Cholesterol >130 mg/dL, are at increased risk for coronary artery disease. The optimal assessment of reaching lipid goals in patients with combined hyperlipidemia is still far from settled and has been an area of revision and modification in recent guidelines. Although controversy remains as to the best single measurement to be used in treatment goals, current focus is on the use of low-density Lipoprotein Cholesterol, non–high-density Lipoprotein Cholesterol, and apoLipoprotein B. This article reviews the use of these 3 biomarkers in assessing cardiovascular risk, and the strategies for managing combined hyperlipidemia.

Peng Yun-sheng - One of the best experts on this subject based on the ideXlab platform.

  • Association between serum hepatitis B virus DNA level with high density Lipoprotein Cholesterol in patients with hepatitis B virus infection
    Journal of Tropical Medicine, 2012
    Co-Authors: Peng Yun-sheng
    Abstract:

    Objective To analyze serum hepatitis B virus DNA copies and high density Lipoprotein Cholesterol levels in patients with hepatitis B virus infection,and explore the association between virus DNA copies and high density Lipoprotein Cholesterol levels. Methods Serum samples were collected from 116 patients with hepatitis B virus infection. Serum hepatitis B virus DNA copies were determined by real-time quantitative polymerase chain reaction. High density Lipoprotein Cholesterol levels were measured with selective inhibition enzymatic methods. Correlation coefficient between serum hepatitis B virus DNA copies and high density Lipoprotein Cholesterol levels was calculated. Result Serum hepatitis B virus DNA copies were inversely correlated with high density Lipoprotein Cholesterol levels (r=-0.5346,P=0.0023) for patients with hepatitis B virus infection. Conclusion High density Lipoprotein Cholesterol may inhibit hepatitis B virus replication.